地西他滨联合半程预激方案诱导缓解治疗老年急性髓系白血病患者的疗效与安全性  

The clinical efficacy and safety of Decitabine combined with half of CAG regimen in older patients with acute myeioid leukemia

作　　者：朱俊锋[1] 郭峰[2] 李佳佳[1] 张凤[1] 

机构地区：[1]安徽蚌埠医学院第一附属医院血液科,233000 [2]安徽六安市人民医院血液科,237000

出　　处：《中华老年医学杂志》2017年第7期777-779,共3页Chinese Journal of Geriatrics

基　　金：基金项目：安徽省高等学校自然科学研究一般项目（KJ20158088by）

摘　　要：目的探讨地西他滨联合半程预激方案治疗老年急性髓系白血病的临床疗效及其安全性。方法选择2010年6月-2016年12月我院收治的29例初诊老年急性髓系白血病患者为研究对象。随机分为观察组（14例）和对照组（15例），观察组给予地西他滨联合半程预激方案治疗；对照组给予全程预激方案治疗。结果观察组有效率高于对照组，但差异无统计学意义（78．6％和53．3％；x2=2．042，P=0．153）；观察组肺部感染率低于对照组（28．6％和73．3％；x2=5．811，P=0．016）；观察组患者生存时间长于对照组[（17．5±5．7）个月和（12．6±6．2）个月；t=2．211，P=0．018]。结论地西他滨联合半程预激方案治疗老年急性髓系白血病安全有效，值得临床推广。Objectives To observe the clinical efficacy and safety of Decitabine combined with half of CAG regimen in older patients with acute myeloid leukemia. Methods 29 older patients with acute myeloid leukemia treated from June 2010 to December 2016 were randomly divided into observation group and control group. Observation group（n= 14）were treated with decitabine combined with half of CAG （aclacinomycin, cytarabine, granulocyte colony-stimulating factor） regimen. The control group（n= 15）were treated with CAG regimen. Results The overall effective rate was higher in observation group（78.6 % ） than in control group（53.5 % ）, but there was no statistically significant difference（x2= 2. 042, P= 0. 153）. The rate of lung infections was significantly lower in observation group（28.6%）than in control group（73.3%）, （x2 =5. 811,P=0. 016）. The survival time of patients was significantly longer in observation group （ 17.5 i 5.7 months） than in control group （ 12.6 ± 6.2 months）, the difference was statistically significant （t = 2. 211, P = 0. 018 ） . Conclusions The treatment program of Decitabine combined with half of CAG regimen in older patients with acute myeloid leukemiais is safe and effective,which is worthy of clinical promotion.

关 键 词：地西他滨 急性髓系白血病 

分 类 号：R733.71[医药卫生—肿瘤]